Andrew is a Venture Professional at Northpond Ventures. Andrew supports Northpond's origination, sourcing, diligence, and monitoring efforts. Prior to joining Northpond Ventures, Andrew was an associate for Booz Allen Hamilton in Arlington, VA working in the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) where he supported the development and management of a high-risk, high-reward research funding portfolio in gene editing and synthetic biology. He has previously worked at Sangamo Biosciences (now Sangamo Therapeutics). Andrew earned his PhD in Microbiology and Immunology from Columbia University and his BA with Honors in Molecular and Cell Biology with an emphasis in Biochemistry and Molecular Biology at UC Berkeley.